ModPath Chat - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

ModPath Chat — Health & Fitness
ModPath Chat

ModPath Chat is the official podcast of Modern Pathology, the journal of the US and Canadian Academy of Pathology (USCAP). ModPath Chat features interviews with authors, opinion leaders and experts on the latest science, technology, and developments in the field of pathology. The monthly podcast series is hosted by Dr. George J. Netto, the Editor-in-Chief of Modern Pathology and the Chair of Pathology at the University of Alabama in Birmingham

Hosted on Acast. See acast.com/privacy for more information.

Latest Episodes:

Machine Learning facilitates assessment of shaved lumpectomy margins Feb 09, 2022

Show notes

Drs. Timothy D’Alfonso, David Ho, and Lee K.Tan from Memorial Sloan Kettering in NY discuss their recent Modern Pathology study describing a new machine learning algorithm that can help pathologists assess shaved margins from lumpectomy specimens. A uniquely developed Deep Multi-Magnification Network (DMMN) was utilized in Whole Slide Images (WSI) in the hope to triage negative margins and allow pathologists to focus on shaves that are positive for DCIS and/or Invasive carcinoma.

Hosted on Acast. See acast.com/privacy for more information.

Meet the Expert: A Conversation with Professor Holger Moch Jan 25, 2022

Show notes

Professor Holger Moch shares with our audience his most inspiring career journey as a physician scientist and a luminary in the field of renal cancers. An enjoyable historical look back at the evolution of the field and the progress in renal tumor classifications.

Hosted on Acast. See acast.com/privacy for more information.

2021 Year in Review Dec 28, 2021

Show notes

In this episode of ModPath CHAT, Dr. George J Netto reviews five of the highly cited manuscripts that were published in Modern Pathology in 2021.

Hosted on Acast. See acast.com/privacy for more information.

NTRK Fusions Dec 07, 2021

Show notes

Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team.

Hosted on Acast. See acast.com/privacy for more information.

DICER1 Tumor Predisposition Syndrome: A chat with Pepper Dehner! Nov 23, 2021

Show notes

Dr. Dehner discusses his four decades journey with an entity that he first described in 1977. Since his initial description of Pleuropulmonary Blastoma (PPB), the neoplasm has become one of the defining entities of DICER1 Syndrome, a rare autosomal dominant familial tumor predisposition disorder with heterozygous DICER1 germline mutation. A fascinating historical perspective and most informative ModPath Chat episode on the wide spectrum of neoplasms that can be encountered in the syndrome awaits the listener. Study by Dehner et al. DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Modern Pathology (2021). https://www.nature.com/articles/s41379-021-00905-8.

Hosted on Acast. See acast.com/privacy for more information.

Re-evaluating tumors of purported specialized prostatic stromal origin: Distinct entities or Heterogenous mesenchymal neoplasms? Nov 09, 2021

Show notes

The host is joined by Dr. Andres Acosta from the Brigham and Women Hospital. Dr Acosta discusses, on behalf of a distinguished group of coauthors, their recent somewhat provocative modern pathology publication proposing that mesenchymal neoplasms of the prostate are morphologically and molecularly heterogeneous lesions that include neoplasms that harbor genetic aberrations seen in specific mesenchymal tumors arising in other anatomic sites, such as soft tissue and the uterus. Study by Acosta et al, Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes. Modern Pathology, 34, 1763–1779 (2021). https://www.nature.com/articles/s41379-021-00818-6.

Hosted on Acast. See acast.com/privacy for more information.

“AstroPath” Substituting cells for cosmic stars, the sky is the limit for digital and computational pathology! Oct 26, 2021

Show notes

In this special “Meet the Expert” episode, two distinguished guests from Johns Hopkins University discuss their pioneering approach of applying methodologies, initially developed for astronomy, to the assessment of biomarkers of tumor microenvironment (TME). The guests are Dr. Janis Taube, director of Dermatopathology at Hopkins, and a co-Director of the TME Core at the Bloomberg-Kimmel Institute of Immunotherapy, and Dr. Alex Szalay, Bloomberg Distinguished Professor of Astronomy and Computer Science at Hopkins and the architect for the Science Archive of the Sloan Digital Sky Survey. The fascinating discussion focuses on an innovative multiplex imaging platform that they co-developed (AstroPath) for multidimensional assessment of spatially resolved interactions at the single-cell level of lung cancer and melanoma.

Hosted on Acast. See acast.com/privacy for more information.

Counting Mitoses: SI(ze) matters! Oct 12, 2021

Show notes

In this episode, Dr. Ian Cree, Head of The WHO Tumour Classification discusses his team's recent open access publication in Modern Pathology. Historically, mitotic figures counting has been done by expressing the number of mitoses per n high power fields (HPFs), ignoring the fact that microscope fields may differ substantially, even at the same high power (×400) magnification. Dr. Cree and coauthors remind all of this variation and its implication on the accuracy of our diagnostic and tumor grading practices. While the expanding adoption of computational digital pathology algorithm will help bring consistency to assessing proliferation activity, our MODPATH Chat guest recommends that counting should be performed per standard international unit of (mm2); with an indication of the area to be counted and the method used (“hotspot” vs “average”). Study by Cree et al, Counting mitoses: SI(ze) matters! Modern Pathology, 34, 1651–1657 (2021). https://www.nature.com/articles/s41379-021-00825-7.

Hosted on Acast. See acast.com/privacy for more information.

The Role of Genotyping in the Diagnosis and Prognostication of Gestational Trophoblastic Disease Sep 29, 2021

Show notes

In this episode of MODPATH CHAT, our guests Dr. Natalia Buza and Dr. Pei Hui from the department of Pathology at Yale University share their approach to the application of DNA genotyping to the diagnosis and prognostication of Hydatidiform moles and Gestational trophoblastic tumors. Genotyping is now the gold standard in the confirmation and subtyping of sporadic hydatidiform moles. DNA genotyping is critical to the separation of gestational trophoblastic neoplasia from non-gestational counterparts/mimics of either germ cell or somatic origin. Modern Pathology, 34, 1658–1672 (2021). https://www.nature.com/articles/s41379-021-00831-9.

Hosted on Acast. See acast.com/privacy for more information.

Regression predicts Sentinel Lymph Node (SLN) status Sep 14, 2021

Show notes

The prognostic significance of regression has long been a matter of debate. Our guest, Professor Richard Scolyer, co-director of the Melanoma Institute Australia discussed his team’s recent findings on the prognostic value of regression, and the presence of regression and/or tumor infiltrating lymphocytes (TIL) in primary cutaneous melanomas predicted sentinel lymph node (SLN) status and survival outcomes. Study by Scolyer et al, Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021. https://www.nature.com/articles/s41379-021-00870-2.

Hosted on Acast. See acast.com/privacy for more information.

Related Podcasts